TROV: Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

New alert via PocketInfo for TROV:

Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

Press Releases: http://trovagene.investorroom.com/press-releases
SEC Filings: http://trovagene.investorroom.com/sec-filings
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8